Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Estrogen Receptor Positive Breast Cancer|Progesterone Receptor Positive Tumor|Recurrent Breast Carcinoma|Stage IA Breast Cancer|Stage IB Breast Cancer|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer
Interventions: DRUG: Exemestane|OTHER: Laboratory Biomarker Analysis|PROCEDURE: Oophorectomy|OTHER: Quality-of-Life Assessment|RADIATION: Radiation Therapy|DRUG: Tamoxifen|DRUG: Triptorelin
Sponsor: ETOP IBCSG Partners Foundation
Collaborators: Breast International Group|Cancer and Leukemia Group B|National Cancer Institute (NCI)|NSABP Foundation Inc|NCIC Clinical Trials Group|North Central Cancer Treatment Group|SWOG Cancer Research Network